AstraZeneca Pharma India Ltd. - Research Center
506820 ASTRAZEN Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Sales | 383.20 | 305.79 | 311.07 | 295.47 | 284.70 |
| Operating profit | 49.39 | 15.06 | 52.76 | 67.25 | 59.85 |
| Interest | -0.07 | 0.61 | 0.50 | 0.15 | 0.09 |
| Gross profit | 58.12 | 24.10 | 60.63 | 75.20 | 67.76 |
| EPS (Rs) | 15.79 | 6.32 | 20.95 | 21.54 | 6.91 |
Quarterly
results in details
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Other income | 8.66 | 9.66 | 8.37 | 8.10 | 8.00 |
| Stock adjustment | 104.95 | -70.76 | -56.62 | -11.34 | -26.70 |
| Raw material | 33.62 | 37.52 | 38.80 | 19.08 | 21.62 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 57.98 | 63.23 | 65.27 | 54.97 | 66.86 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 137.26 | 260.74 | 210.86 | 165.51 | 163.08 |
| Provisions made | - | - | - | - | - |
| Depreciation | 3.76 | 3.70 | 3.67 | 3.80 | 4.25 |
| Taxation | 14.88 | 4.60 | 21.01 | 17.54 | 6.01 |
| Net profit / loss | 39.48 | 15.80 | 52.37 | 53.86 | 17.27 |
| Extra ordinary item | - | - | 16.43 | - | -40.23 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 12.89 | 4.92 | 16.96 | 22.76 | 21.02 |
| GPM (%) | 14.83 | 7.64 | 18.98 | 24.77 | 23.15 |
| NPM (%) | 10.07 | 5.01 | 16.39 | 17.74 | 5.90 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis